Search Back New search Go to resultsDiseaseMain groupSupportive Therapy, ToxicityProtocol groupImmunodeficienciesDiseaseAntibody Deficiency, PrimarySubgroupICD10MeSHPrimary Immunodeficiency DiseasesSequenceRHUH(800/1600/2400)/SCIgG(10/20/30), prim. Antibody deficiency, C1 (PID1726) -|- RHUH2400/SCIgG30, C2+ (PID1731)ChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceHuman immunoglobulin (SCIg)Recombinant human hyaluronidaseSupportive substanceHuman immunoglobulin (SCIg)Recombinant human hyaluronidaseSupportive substanceHuman immunoglobulin (SCIg)Recombinant human hyaluronidaseSupportive substanceHuman immunoglobulin (SCIg)Recombinant human hyaluronidaseNo. Substances2Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationTherapy phaseTherapy intentiondisease controlsupportiveRisksAllergic ReactionHeadachePain only studiesPublicationAuthorWasserman RLDiseasePrimäre HypogammaglobulinämieOriginAllergy/Immunology Research Center of North Texas, Dallas, USAProtocols in Revision 2 protocols foundProtocols under revision.Recombinant Human Hyaluronidase (800/1600/2400) / Subcutaneous Immunoglobulin-G (10/20/30), Primary Antibody Deficiency, Cycle 1 (PID1726 V1.0)Recombinant Human Hyaluronidase 2400 / Subcutaneous Immunoglobulin-G 30, Primary Antibody Deficiency, Cycle 2+ (PID1731 V1.0)
